Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:ALTNASDAQ:ARQTNASDAQ:BEAM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$29.80+0.7%$28.66$23.42▼$62.58$1.73B0.77695,037 shs440,665 shsALTAltimmune$5.71-1.0%$5.11$3.55▼$11.16$463.12M1.132.82 million shs1.65 million shsARQTArcutis Biotherapeutics$13.98+2.3%$14.56$6.99▼$17.75$1.67B1.872.29 million shs1.65 million shsBEAMBeam Therapeutics$16.83-2.4%$18.43$13.53▼$35.25$1.73B2.351.45 million shs962,009 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+0.71%+2.12%+4.87%-15.38%-10.89%ALTAltimmune-1.04%+2.33%+14.91%-11.20%-27.63%ARQTArcutis Biotherapeutics+2.34%-0.92%-3.35%+7.37%+40.93%BEAMBeam Therapeutics-2.38%-5.93%-15.36%-44.69%-32.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals3.9542 of 5 stars3.31.00.04.23.00.81.9ALTAltimmune2.4852 of 5 stars3.51.00.00.02.83.30.6ARQTArcutis Biotherapeutics2.9457 of 5 stars4.41.00.00.03.41.70.6BEAMBeam Therapeutics3.1274 of 5 stars4.51.00.00.03.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.56Moderate Buy$56.0087.92% UpsideALTAltimmune 3.00Buy$20.20253.77% UpsideARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8034.48% UpsideBEAMBeam Therapeutics 3.00Buy$48.75189.66% UpsideCurrent Analyst Ratings BreakdownLatest ALT, BEAM, ARQT, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/7/2025BEAMBeam TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $55.005/7/2025BEAMBeam TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.005/7/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.004/9/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/7/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/3/2025ARQTArcutis BiotherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/3/2025ARQTArcutis BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$37.04M46.60N/AN/A$27.02 per share1.10ALTAltimmune$20K23,156.05N/AN/A$2.75 per share2.08ARQTArcutis Biotherapeutics$212.82M7.83N/AN/A$0.94 per share14.87BEAMBeam Therapeutics$63.58M26.62N/AN/A$12.04 per share1.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.242.63N/AN/A1,845.92%-2.51%-2.26%8/7/2025 (Estimated)ALTAltimmune-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)ARQTArcutis Biotherapeutics-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%N/ABEAMBeam Therapeutics-$132.53M-$4.61N/AN/AN/A-41.07%-16.22%-10.94%8/5/2025 (Estimated)Latest ALT, BEAM, ARQT, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million2/27/2025Q4 2024ALTAltimmune-$0.34-$0.33+$0.01-$0.33$0.00 million$0.01 million2/25/2025Q4 2024ARQTArcutis Biotherapeutics-$0.28-$0.09+$0.19-$0.09$60.52 million$71.36 million2/25/2025Q4 2024BEAMBeam Therapeutics-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABEAMBeam Therapeutics$0.905.35%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A11.9011.56ALTAltimmuneN/A16.8716.87ARQTArcutis Biotherapeutics0.672.462.38BEAMBeam TherapeuticsN/A5.695.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AALTAltimmune78.05%ARQTArcutis BiotherapeuticsN/ABEAMBeam Therapeutics99.68%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%ALTAltimmune4.10%ARQTArcutis Biotherapeutics9.40%BEAMBeam Therapeutics4.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million54.47 millionOptionableALTAltimmune5081.11 million68.21 millionOptionableARQTArcutis Biotherapeutics150119.20 million105.93 millionOptionableBEAMBeam Therapeutics510100.56 million79.33 millionOptionableALT, BEAM, ARQT, and AGIO HeadlinesRecent News About These CompaniesGoogle Beam Futuristic AI-Powered 3D Video Chats Are Coming This YearMay 23 at 10:37 AM | msn.comTwinbeech Capital LP Purchases 69,456 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)May 23 at 5:57 AM | marketbeat.comRafferty Asset Management LLC Has $2.76 Million Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)May 22 at 4:42 AM | marketbeat.comPoint72 Asset Management L.P. Buys Shares of 193,356 Beam Therapeutics Inc. (NASDAQ:BEAM)May 22 at 4:42 AM | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Tang Capital Management LLCMay 20, 2025 | marketbeat.comRaiffeisen Bank International AG Invests $1.26 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)May 19, 2025 | marketbeat.comPolar Asset Management Partners Inc. Acquires 187,455 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)May 18, 2025 | marketbeat.comHudson Bay Capital Management LP Sells 15,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)May 16, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust CorpMay 16, 2025 | marketbeat.comAlgert Global LLC Has $233,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM)May 15, 2025 | marketbeat.comBeam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 CongressMay 14, 2025 | globenewswire.comBeam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare ConferenceMay 13, 2025 | globenewswire.comHC Wainwright Issues Positive Forecast for BEAM EarningsMay 13, 2025 | marketbeat.comBeam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)May 12, 2025 | globenewswire.comLeerink Partnrs Issues Optimistic Forecast for BEAM EarningsMay 11, 2025 | marketbeat.comQ2 EPS Forecast for Beam Therapeutics Reduced by AnalystMay 11, 2025 | marketbeat.comFarallon Capital Management LLC Purchases 31,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)May 11, 2025 | marketbeat.comCrestline Management LP Increases Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)May 11, 2025 | marketbeat.comTudor Investment Corp ET AL Sells 16,242 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)May 11, 2025 | marketbeat.comQ2 Earnings Estimate for Beam Therapeutics Issued By WedbushMay 10, 2025 | marketbeat.comWhy Beam Therapeutics Inc.’s (BEAM) Stock Is Up 7.36%May 9, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Analysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueArcher Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue LaunchBy Jeffrey Neal Johnson | May 14, 2025View Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue LaunchWill Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?By Gabriel Osorio-Mazilli | May 22, 2025View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?Hims & Hers Stock Chart Points to Strong Bullish ContinuationBy Thomas Hughes | May 20, 2025View Hims & Hers Stock Chart Points to Strong Bullish ContinuationALT, BEAM, ARQT, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$29.80 +0.21 (+0.71%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$29.79 -0.01 (-0.03%) As of 05/23/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Altimmune NASDAQ:ALT$5.71 -0.06 (-1.04%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.69 -0.02 (-0.35%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Arcutis Biotherapeutics NASDAQ:ARQT$13.98 +0.32 (+2.34%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$14.10 +0.12 (+0.82%) As of 05/23/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Beam Therapeutics NASDAQ:BEAM$16.83 -0.41 (-2.38%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$16.98 +0.15 (+0.89%) As of 05/23/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
